- Global Pharma News & Resources

Vitiligo Drugs Market Set for Rapid Growth, to Reach around 12.6% of CAGR by 2027 | Industry Key Players, Trends and Development | Coherent Market Insights


Vitiligo is a long-term condition where pale white patches develop on the skin. It can affect eyes, mouth, and hair, however, varies from person to person. Treatment may improve the appearance of the skin but doesn’t cure the disease. Psoralens, Corticosteroids, and Calcineurin Inhibitors are some major drugs commonly used by doctors for the treatment of vitiligo.

Request Here For Market Latest Insights:

COVID Impact:

The outbreak of COVID-19 has placed an economic burden on the private healthcare sector, due to lockdowns in various countries worldwide. The industry is facing challenges with regards to declining consumables, equipment, manpower, outpatient’s visits, and other resources to ensure safety of the patients. The pandemic has severely disrupts the entire supply chain of the healthcare industry, from raw materials to manufacturing and delivery.

Moreover, the pandemic has affected the conduct of clinical trials due to non-availability of testing site staff, restrictions for travel, and others. Thus, the COVID-19 outbreak has negatively impacted the global vitiligo drug market.


Increasing focus towards the development of safe and effective vitiligo treatment is expected to drive the global vitiligo drug market growth over the forecast period. For instance, in October 2018, STRATA Skin Sciences announced the launch of the new XTRAC S3 308nm Laser system for the treatment of skin disorders, such as vitiligo and psoriasis.

Market players are adopting various inorganic strategies, such as product launches, clinical trials, partnership, and collaborations, to meet the increasing demand for vitiligo drugs, which in turn is expected to augment the global vitiligo drug market growth. For instance, in June 2019, Incyte announced positive results from a phase 2 study of Ruxolitinib cream in patients with vitiligo. Moreover, in 2014, Dr. Reddy’s Laboratories launched the Melgain lotion for treatment of vitiligo as well as skin pigmentation disorders in India.

Key Players:

Key players operating in the global vitiligo drugs market are Incyte Corporation, Dermavant Sciences Inc., Aclaris Therapeutics Inc., Bristol – Myers Squibb, Dr. Reddy’s Laboratories, Pfizer, Boston Pharmaceuticals, Arcutis Biotherapeutics, Temprian Therapeutics, Villaris Therapeutics, Applied Biology, Clinuvel Pharmaceuticals, and Arrien Pharmaceuticals LLC.

Purchase this Report at Discount Of US $2000 Flat OFF –

Table of Content

Global Vitiligo Drugs Market Research Report
Section 1: Global Vitiligo Drugs Industry Overview
Section 2: Global Economic Impact on Vitiligo Drugs Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Vitiligo Drugs Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Vitiligo Drugs Market Forecast

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 22-Sep-2021